Medical Xpress August 15, 2024
Elodie MAZEIN with Beiyi SEOW in Washington

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

Their statements came after US President Joe Biden and Vice President Kamala Harris announced a deal to lower costs of the first 10 drugs picked for Medicare price talks.

The agreement with drugmakers—who said they came on board with negotiations as they had no choice—is set to save seniors in the United States $1.5 billion in out-of-pocket costs.

It is the result of months of negotiations and is anticipated to save Medicare $6 billion in the first year alone, said Biden, referring to the federal health insurance for seniors.

While the announcement...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
Survey Suggests Pharma Industry Still Struggling with Digital Transformation
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Putting Patients First by Extending the Reach of World-Class Care
Biotech startups are built on venture capital. Track funding rounds here.

Share This Article